Skip To Main Content
Silvia Barbazza on Muck Rack

Silvia Barbazza

As seen in: Wiley Online Library, BMJ Open
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Silvia

Contact Silvia, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Rice Bran Supplements the Nutritional Density of Ready‐to‐Use Therapeutic Foods: A Targeted Nutrient and Non‐Targeted Metabolomic Analysis

|
By Annika Weber, Sahar B. Toulabi, Silvia Barbazza, Emma S. Bovaird
| Wiley Online Library Verified
1 Introduction Ready-to-use therapeutic foods (RUTFs) are nutrient-dense, high-calorie foods used in the treatment of uncomplicated severe acute malnutrition in children aged 6–59 months (FAO et al. 2023). The benefits of RUTFs include the ability to treat severe acute malnutrition in a community context, as many cases do not require hospitalization or are in rural areas where hospital access may not be feasible.
Open in Who Shared Issue with article?

Solutions to Enhance Health with Alternative Treatments (SEHAT) protocol: a double-blinded randomised controlled trial for gut microbiota-targeted treatment of severe acute malnutrition using rice bran in ready-to-use therapeutic foods in Indonesia

|
By Annika Weber, Silvia Barbazza, Moretta D Fauzi, Asrinisa Rachmadewi
| BMJ Open Verified
Methods This study is an intention to treat (ITT), double-blinded, comparative, RCT and the protocol was designed as a collaboration between Colorado State University (CSU), USA, the Institut de Recherche pour le Développement, France, and PT Santulita Vikasa (Savica), Indonesia. The SEHAT study is funded by the Thrasher Research Fund. Enrolment began in December 2022 and the trial is expected to continue through September 2023.
Open in Who Shared Issue with article?
See all 2 articles